(en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, «Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis», American Journal of Respiratory and Critical Care Medicine, vol.167, no11, , p.1472-1477. (PMID12569078, DOI10.1164/rccm.200206-626OC, lire en ligne)
(en) «Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.», MMWR Recommendations and Reports, vol.49, noRR-6, , p.1-51 (PMID10881762, lire en ligne)
(en) «Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis», The Lancet, vol.1, no8213, , p.171-174 (PMID6109855, DOI10.1016/S0140-6736(02)95623-0, lire en ligne)
(en) East and Central African/British Medical Research Council Fifth Collaborative Study, «Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis», Tubercle, vol.64, no3, , p.153-166 (PMID6356538, DOI10.1016/0041-3879(83)90011-9, lire en ligne)
(en) British Thoracic Society, «A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond», British Journal of Diseases of the Chest, vol.78, , p.330-336. (PMID6386028, DOI10.1016/0007-0971(84)90165-7, lire en ligne)
(en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, «Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis», American Journal of Respiratory and Critical Care Medicine, vol.167, no11, , p.1472-1477. (PMID12569078, DOI10.1164/rccm.200206-626OC, lire en ligne)
(en) W Shi, X Zhang, X Jiang, H Yuan, JS Lee, CE Barry, H Wang, W Zhang et Y Zhang, «Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy», Science, vol.333, no6049, , p.1630-1632 (PMID21835980, PMCID3502614, DOI10.1126/science.1208813)
(en) Y Zhang et D Mitchison, «The curious characteristics of pyrazinamide: a review», Int. J. Tuberc. Lung Dis., vol.7, no1, , p.6-21 (PMID12701830, lire en ligne)
(en) «Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis», The Lancet, vol.1, no8213, , p.171-174 (PMID6109855, DOI10.1016/S0140-6736(02)95623-0, lire en ligne)
(en) «Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.», MMWR Recommendations and Reports, vol.49, noRR-6, , p.1-51 (PMID10881762, lire en ligne)
(en) East and Central African/British Medical Research Council Fifth Collaborative Study, «Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis», Tubercle, vol.64, no3, , p.153-166 (PMID6356538, DOI10.1016/0041-3879(83)90011-9, lire en ligne)
(en) British Thoracic Society, «A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond», British Journal of Diseases of the Chest, vol.78, , p.330-336. (PMID6386028, DOI10.1016/0007-0971(84)90165-7, lire en ligne)
(en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, «Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis», American Journal of Respiratory and Critical Care Medicine, vol.167, no11, , p.1472-1477. (PMID12569078, DOI10.1164/rccm.200206-626OC, lire en ligne)
(en) Y Zhang et D Mitchison, «The curious characteristics of pyrazinamide: a review», Int. J. Tuberc. Lung Dis., vol.7, no1, , p.6-21 (PMID12701830, lire en ligne)
(en) O Zimhony, JS Cox, JT Welch, C Vilchèze et WR Jacobs, «Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.», Nature Medecine, vol.6, no9, , p.1043-1047 (PMID10973326)
(en) W Shi, X Zhang, X Jiang, H Yuan, JS Lee, CE Barry, H Wang, W Zhang et Y Zhang, «Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy», Science, vol.333, no6049, , p.1630-1632 (PMID21835980, PMCID3502614, DOI10.1126/science.1208813)
(en) «Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis», The Lancet, vol.1, no8213, , p.171-174 (PMID6109855, DOI10.1016/S0140-6736(02)95623-0, lire en ligne)
(en) East and Central African/British Medical Research Council Fifth Collaborative Study, «Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis», Tubercle, vol.64, no3, , p.153-166 (PMID6356538, DOI10.1016/0041-3879(83)90011-9, lire en ligne)
(en) British Thoracic Society, «A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond», British Journal of Diseases of the Chest, vol.78, , p.330-336. (PMID6386028, DOI10.1016/0007-0971(84)90165-7, lire en ligne)